Casper joined Lundbeckfonden Ventures in 2009 and is currently a board member of Aura Biosciences, Atox Bio, Dysis Medical and Sanifit. Prior to joining Ventures, Casper gained broad international experience from almost 20 years in the pharma and biotech industry, covering areas such as chemistry, project management, outsourcing, international quality audits, business development, alliance management, and general management.
Casper was previously CEO of ilochip A/S, a venture-backed company focused on development of diagnostic biochips. Before this, he held various positions at H. Lundbeck A/S, most recently in corporate business development and strategy.
Prior to taking up his position at H. Lundbeck, Casper worked for Novo Nordisk A/S and Niels Clauson-Kaas A/S. While working at H. Lundbeck A/S, he was a member of the board of directors of Lundbeck Foundation and the board of directors of Lundbeckfond Invest A/S as an employee representative. Casper has an MSc in organic chemistry and an MBA in Innovation and New Business Creation, both from the Technical University of Denmark.
Direct +45 3912 8081